Dataset from A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers

The purpose of this study was to evaluate the safety and immune response to a single
intramuscular (IM) dose of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3)
in healthy pregnant women 18-40 years of age and in infants born to vaccinated mothers.